Oppenheimer maintains Outperform on Climb Bio; PT raised to $25
Oppenheimer maintained its Outperform rating on Climb Bio and raised its price target to $25.00 per share from $18.00, per Benzinga.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.